iData Insights

Diabetic Neuropathy - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 27, 2016 16:19 IST

Diabetic Neuropathy - Pipeline Review, H2 2015 Summary Global Markets Direct s, Diabetic Neuropathy - Pipeline Review, H2 2015, provides an overview of the Diabetic Neuropathys therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Diabetic Neuropathy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Diabetic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173375/diabetic-neuropathy-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173375/diabetic-neuropathy-pipeline-review-h2-2015

Table of Contents

Introduction 9

Global Markets Direct Report Coverage 9

Diabetic Neuropathy Overview 10

Therapeutics Development 11

Pipeline Products for Diabetic Neuropathy - Overview 11

Pipeline Products for Diabetic Neuropathy - Comparative Analysis 12

Diabetic Neuropathy - Therapeutics under Development by Companies 13

Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes 15

Diabetic Neuropathy - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Diabetic Neuropathy - Products under Development by Companies 19

Diabetic Neuropathy - Products under Investigation by Universities/Institutes 20

Diabetic Neuropathy - Companies Involved in Therapeutics Development 21

Araim Pharmaceuticals Inc. 21

Bristol-Myers Squibb Company 22

Cebix Incorporated 23

Celgene Corporation 24

Glucox Biotech AB 25

Longevity Biotech, Inc 26

Lpath, Inc. 27

Neuralstem, Inc. 28

NovaLead Pharma Pvt. Ltd. 29

Nuvo Research Inc. 30

Omeros Corporation 31

Pfizer Inc. 32

R-Tech Ueno, Ltd. 33

Reata Pharmaceuticals, Inc. 34

Relief Therapeutics S.A. 35

Sumitomo Dainippon Pharma Co., Ltd. 36

Virobay Inc. 37

ViroMed Co., Ltd. 38

Diabetic Neuropathy - Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Target 40

Assessment by Mechanism of Action 42

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 48

atexakin alfa - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

benfotiamine - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

BNV-222 - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

CBX-129801 - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

cibinetide - Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

CMB-200 - Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Cyndacel-M - Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Drug for Pain - Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Flexicaine - Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

ketoprofen - Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

LBT-3627 - Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Lpathomab - Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

NLP-198 - Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

NSI-566 - Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

OMS-721 - Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

PDA-002 - Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

PF-05089771 - Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

pirenzepine hydrochloride - Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

ranirestat - Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

RTA-901 - Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

RTU-1096 - Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

Small Molecule to Agonize Kv7.2 for Neuropathic Pain and Diabetic Neuropathy - Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small Molecules for Diabetic Neuropathy - Drug Profile 84

Product Description 84

Mechanism of Action 84

R&D Progress 84

Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

VBY-285 - Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

VM-202 - Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

Diabetic Neuropathy - Recent Pipeline Updates 89

Diabetic Neuropathy - Dormant Projects 106

Diabetic Neuropathy - Discontinued Products 108

Diabetic Neuropathy - Product Development Milestones 109

Featured News & Press Releases 109

Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 109

Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 110

Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 111

Sep 07, 2011: Cebix To Chair Symposium On C-Peptide And Pathophysiology Of Diabetes At EASD Annual Meeting 111

May 11, 2011: Dainippon Sumitomo Pharma Announces Results Of Phase II Clinical Trial For Ranirestat For Diabetic Complications 112

Mar 18, 2011: ViroMed Enrolls Final Patient for US VM202-DPN Phase I/II Clinical Trial 113

Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 113

Sep 29, 2005: Dainippon and Eisai Signs Licensing Agreement for A Potential New Treatment For Diabetic Neuropathy 113

Appendix 115

Methodology 115

Coverage 115

Secondary Research 115

Primary Research 115

Expert Panel Validation 115

Contact Us 115

Disclaimer 116"

Read More http://www.idatainsights.com/reports-landing-page.php?id=173375/diabetic-neuropathy-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects